Just Biotherapeutics and Pandion Therapeutics announced that they have entered into an agreement for the development and cGMP clinical manufacturing by Just of Pandion’s lead program.
Just will provide Pandion with a suite of services leveraging Just’s fully integrated technology platform, J.DESIGN. The services include cell line development, process development, and Phase 1 cGMP clinical manufacturing of a selected drug candidate to expedite Pandion’s IND filing by the end of 2019.
“We value our partnership with Just to accelerate our product candidates through development and into the clinic,” said Dr. Jo Viney, Chief Scientific Officer of Pandion. “Just’s expertise and guidance combined with their unique technology platform will play a critical role in the successful production of our molecules.”
“We are delighted to be working with the experienced and dynamic team at Pandion on the development and manufacturing of Pandion’s lead program, PT101,” said Dr. James Thomas, Co-founder and Chief Executive Officer of Just.